CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acorda Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acorda Therapeutics Inc
TWO BLUE HILL PLAZA
Phone: (914) 347-4300p:914 347-4300 PEARL RIVER, NY  10965  United States Ticker: ACORQACORQ
Filed for Bankruptcy on 4/1/2024
Case #24-22284, filed in the U.S. Bankruptcy Court for the Southern District of New York (White Plains)
Business Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes-Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board John P.Kelley 69 11/25/2019 12/1/2008
President, Chief Executive Officer, Director RonCohen 67 1/1/1995 1/1/1995
Chief Financial Officer MichaelGesser 60 11/8/2021 11/8/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Acorda Therapeutics Limited 1 Bartholomew Lane London United Kingdom
Biotie Therapies Corp Joukahaisenkatu 6 TURKU Finland
Biotie Therapies Corp (ADR) Joukahaisenkatu 6 TURKU Finland
4 additional Subsidiary records available in full report.

Business Names
Business Name
ACOR
Acorda Therapeutics Ireland Limited
Acorda Therapeutics Ireland Limited (Ireland)
19 additional Business Names available in full report.

General Information
Number of Employees: 102 (As of 3/1/2024)
Outstanding Shares: 1,242,098 (As of 3/27/2024)
Shareholders: 10
Stock Exchange: OTC
Federal Tax Id: 133831168
Fax Number: (914) 347-4560


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024